ACCD Stock Overview
Engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Accolade, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.67 |
| 52 Week High | US$15.36 |
| 52 Week Low | US$3.35 |
| Beta | 1.99 |
| 11 Month Change | -13.85% |
| 3 Month Change | -7.09% |
| 1 Year Change | -48.74% |
| 33 Year Change | -90.55% |
| 5 Year Change | n/a |
| Change since IPO | -87.64% |
Recent News & Updates
Accolade: Consider Both Short-Term Revenue Outlook And Rumored Takeover
Sep 09Slammed 50% Accolade, Inc. (NASDAQ:ACCD) Screens Well Here But There Might Be A Catch
Jun 29
Recent updates
Accolade: Consider Both Short-Term Revenue Outlook And Rumored Takeover
Sep 09Slammed 50% Accolade, Inc. (NASDAQ:ACCD) Screens Well Here But There Might Be A Catch
Jun 29Accolade: Mixed Guidance (Rating Downgrade)
Jun 28Does Accolade (NASDAQ:ACCD) Have A Healthy Balance Sheet?
Jun 05Accolade: Staying Bullish On Favorable Developments
Apr 05Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price
Feb 17Accolade: Remain Confident That FY25 Guided Growth Is Achievable
Jan 17Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)
Jan 11Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge
Jun 13Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?
May 02An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued
Feb 05Accolade: Inching Closer To Profitability
Oct 17Accolade Q2 2023 Earnings Preview
Oct 05Accolade: Fair And Reasonably Priced, But Needs More Time
Aug 09Accolade Q1 2023 Earnings Preview
Jun 29Accolade: Little Recent Applause
Mar 28Accolade Impresses With Revenue Growth But Faces Operating Losses
Dec 16Accolade: I May Add To My Position
Oct 18Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 11Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation
May 06Shareholder Returns
| ACCD | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -7.6% | 1.6% | 1.5% |
| 1Y | -48.7% | 7.7% | 33.1% |
Return vs Industry: ACCD underperformed the US Healthcare industry which returned 7.7% over the past year.
Return vs Market: ACCD underperformed the US Market which returned 33.1% over the past year.
Price Volatility
| ACCD volatility | |
|---|---|
| ACCD Average Weekly Movement | 9.3% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACCD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACCD's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,400 | Raj Singh | www.accolade.com |
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions.
Accolade, Inc. Fundamentals Summary
| ACCD fundamental statistics | |
|---|---|
| Market cap | US$305.24m |
| Earnings (TTM) | -US$80.10m |
| Revenue (TTM) | US$441.03m |
0.7x
P/S Ratio-3.7x
P/E RatioIs ACCD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACCD income statement (TTM) | |
|---|---|
| Revenue | US$441.03m |
| Cost of Revenue | US$228.29m |
| Gross Profit | US$212.74m |
| Other Expenses | US$292.84m |
| Earnings | -US$80.10m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 48.24% |
| Net Profit Margin | -18.16% |
| Debt/Equity Ratio | 49.4% |
How did ACCD perform over the long term?
See historical performance and comparison